Nicotinamide: A Chemoprevention for Nonmelanoma Skin Cancer

Aaron Nethercott, Mercer University College of Pharmacy

The sun produces ultraviolet (UV) radiation. This radiation is believed to cause damage to deoxyribonucleic acid (DNA) and decrease immune repair functions in the skin which leads to nonmelanoma skin cancer.  It is also theorized that the oxidative stress of UV radiation decreases the levels of adenosine triphosphate (ATP).  Nicotinamide is a vital part of the coenzymes nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotide phosphate (NADPH).  These coenzymes have been found to be essential components of over 200 enzymatic reactions, including the production of ATP.  It is suggested that increasing the levels of ATP nicotinamide can help protect against nonmelanoma skin cancers. [1]

Continue reading


Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Hoa Tang, Mercer University College of Pharmacy

It is estimated that in 2015, there will be more than 73,000 new cases from melanoma diagnoses and about 10,000 deaths caused by melanoma in the United States.1 Checkpoint inhibitors and the mitogen-activated protein kinase (MAPK) pathway inhibitors are suggested to use for patients with advanced melanoma.2 Ipilimumab, which is an anti cytotoxic T-lymphocyte- associated antigen 4 (CTLA-4) and nivolumab, which is an anti- programmed cell death 1 (PD-1) monoclonal antibody, are checkpoint inhibitors. A review of combination therapy for treatment of advanced melanoma notes that dual immune-ckeckpoint inhibitors may have potential for improve clinical outcomes due to the distinct mechanism of actions.3

A recently published study compared the combination of nivolumab and ipilimumab with ipilimumab monotherapy in patients with advanced melanoma. 4

Continue reading